Elevating the Caregiver’s Voice for People Living with Severe Epilepsy: Jazz at AES 2022
Jazz is committed to developing critical medicines for people living with serious neurological conditions including epilepsy. At this year’s 2022 American Epilepsy Society (AES) annual meeting, we will present data from six abstracts showcasing Jazz’s commitment to providing medicines for people living with rare forms of epilepsy with few treatment options.
Receiving a diagnosis of any kind has implications not just for the person on the receiving end, but also for their family, friends and the people closest to them. As part of our commitment to patients and their care teams, this National Family Caregivers Month, we shine a light on this essential role and its many nuances.
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.
You are now leaving www.JazzPharma.com. Thank you for visiting. The information on the website you are entering is intended for visitors in the United States only.
